Ocean extends patent rights for idiopathic pulmonary fibrosis discovery

Ocean Biomedical announced that Scientific Co-founder Dr. Jack Elias, MD received notice from the European Patent Office of its intention to grant European patent rights for Methods and Compositions relating to the treatment of fibrosis using Ocean’s anti-Chitinase 1 small molecule candidate, a new target discovered by Dr. Elias that appears to be a major factor in controlling-and inhibiting-fibrosis progression. Ocean’s approach has shown an 85%-90% reduction in collagen accumulation in four “gold standard” IPF and HPS pulmonary fibrosis animal models. This treatment approach is anticipated to be well-tolerated based on data from original clinical studies and recent EPA data. “Combining innovative science with a great management team has potential for great impact,” said Dr. Chirinjeev Kathuria, Ocean Biomedical’s co-founder and Executive Chairman. “We are pleased to receive this patent extension and look forward to getting new drugs to patients in Europe and the world.”